Anaphylaxis in the Emergency Department Unit: Before and during COVID‐19

Özyiğit, Leyla Pur; Khalil, Ghayyur; Choudhry, Taimour; Williams, Mark A.; Khan, Nasreen

doi:10.1111/all.14873

Cited by 6 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Airborne pollen concentration, dietary habits, lockdown regulations, climate and comorbidities might be responsible for inconsistent findings of prevalence of allergy in COVID-19 patients manifestations presented before the pandemic by 52% of patients were classified as mild, according to the Brown grading system, whilst during the pandemic the majority of patients (80%) experienced moderate systemic allergic reactions. 41…”

Section: Prevalence Of Allergy and Asthma In Covid-19 Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances and developments in COVID‐19 in the context of allergic diseases

Ding

Sun

Sokołowska

et al. 2021

Clinical & Translational All

View full text Add to dashboard Cite

Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.

show abstract

Section: Prevalence Of Allergy and Asthma In Covid-19 Patientsmentioning

confidence: 99%

“…The clinical manifestations presented before the pandemic by 52% of patients were classified as mild, according to the Brown grading system, whilst during the pandemic the majority of patients (80%) experienced moderate systemic allergic reactions. 41 …”

Section: Prevalence Of Allergy and Asthma In Covid‐19 Patientsmentioning

confidence: 99%

Recent advances and developments in COVID‐19 in the context of allergic diseases

Ding

Sun

Sokołowska

et al. 2021

Clinical & Translational All

View full text Add to dashboard Cite

show abstract

“…2 For children and youth with food allergies (FA), the early COVID-19 pandemic led to immediate changes to allergy-related services 3 ; emergency department visits for anaphylaxis also decreased. 4 Youth whose parents report negative impacts of COVID-19 have also reported poorer well-being, affected by difficulties accessing "safe" foods and health services. 5 Moderate anxiety in parents of children with FA is generally adaptive given risks of allergen exposure.…”

Section: Decreased Food Allergy-specific Anxiety and Increased Genera...mentioning

confidence: 99%

“…3 Pegloticase is a recombinant mammalian uricase derived from a genetically modified strain of Escherichia coli complexed to a 10,000 Da PEG molecule. 4 It has a half-life of 8 to 14 days and is infused every 2 weeks. 4 Pegloticase is known to be associated with infusion and hypersensitivity reactions.…”

Section: A Case Of Coronavirus Disease 2019 Messenger Rna Vaccine Tol...mentioning

confidence: 99%

“…4 It has a half-life of 8 to 14 days and is infused every 2 weeks. 4 Pegloticase is known to be associated with infusion and hypersensitivity reactions. 5 Using data from the US Food and Drug Administration Adverse Event Reporting System, we found that between 2010 and 2019, 5% of all adverse events were reported as anaphylaxis; most of the events were infusion reactions or decreased efficacy.…”

Section: A Case Of Coronavirus Disease 2019 Messenger Rna Vaccine Tol...mentioning

confidence: 99%

See 1 more Smart Citation

Decreased food allergy-specific anxiety and increased general anxiety in parents of children with food allergies during the coronavirus disease 2019 pandemic

Westwell‐Roper

Soller

et al. 2022

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Incidence and trends of anaphylaxis among inpatients from 2003 to 2023 in Wuhan, China: A multicenter retrospective study

Li,

Huang,

et al. 2024

World Allergy Organization Journal

View full text Add to dashboard Cite

Anaphylaxis in the Emergency Department Unit: Before and during COVID‐19

Cited by 6 publications

References 3 publications

Recent advances and developments in COVID‐19 in the context of allergic diseases

Recent advances and developments in COVID‐19 in the context of allergic diseases

Decreased food allergy-specific anxiety and increased general anxiety in parents of children with food allergies during the coronavirus disease 2019 pandemic

Incidence and trends of anaphylaxis among inpatients from 2003 to 2023 in Wuhan, China: A multicenter retrospective study

Contact Info

Product

Resources

About